Clare Scott

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A Ledermann, Ursula A Matulonis, Amit M Oza, Ilan Bruchim, Tomasz Huzarski, Charlie Gourley, Philipp Harter, Ignace Vergote, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tsveta Milenkova, Eric Pujade-Lauraine, Val Gebski, Chee K Lee

Journal article  |  2021  |  EUROPEAN JOURNAL OF CANCER

BACKGROUND: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRC..

Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN

Imogen Caldwell, David Byrne, Stephen Lade, Tim Akhurst, Adrian Minson, Michael Dickinson, Ella Thompson, Clare Scott, Piers Blombery

Journal article  |  2021  |  LEUKEMIA & LYMPHOMA

CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

Zhen Xu, Cassandra J Vandenberg, Elizabeth Lieschke, Ladina Di Rago, Clare L Scott, Ian J Majewski

Journal article  |  2021  |  MOLECULAR CANCER RESEARCH

Patients with cancer treated with PARP inhibitors (PARPi) experience various side effects, with hematologic toxicity being most co..

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.

Ksenija Nesic, Olga Kondrashova, Rachel M Hurley, Cordelia D McGehee, Cassandra J Vandenberg, Gwo-Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield-Artin, Marc Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Australian Ovarian Cancer Study, et al.

Journal article  |  2021  |  Cancer Res

In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defectiv..

Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis

Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, Jonathan A Ledermann, Robert L Coleman, Mansoor R Mirza, Ursula A Matulonis, Eric Pujade-Lauraine, Ralph Bloomfield, Sandra Goble, Ping Wang, Rosalind M Glasspool, Clare L Scott

Journal article  |  2021  |  CANCER

BACKGROUND: The authors performed a meta-analysis to better quantify the benefit of maintenance poly(ADP-ribose) polymerase inhibi..

Abstract 1074: Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  Experimental and Molecular Therapeutics

Abstract 2057: BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts

Ksenija Nesic, Cassandra J Vandenberg, Olga Kondrashova, John J Krais, Neil Johnson, Elizabeth M Swisher, Matthew J Wakefield, Clare L Scott

Conference Proceedings  |  2021  |  Molecular and Cellular Biology/Genetics

T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review

Jessica WY Wu, Sudiksha Dand, Lachlan Doig, Anthony T Papenfuss, Clare L Scott, Gwo Ho, Joshua D Ooi

Journal article  |  2021  |  FRONTIERS IN IMMUNOLOGY

Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive a..

WhiMSICAL: A global Waldenstrom's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes

Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, Peter L DeNardis, Javier Haurat, Marita Black, Stephen Opat, Damien Kee, Shirley D'Sa, Marie Jose Kersten, Ruth L Spearing, Maria Lia Palomba, Adam J Olszewski, Carl Harrington, Clare L Scott, Judith Trotman

Journal article  |  2021  |  AMERICAN JOURNAL OF HEMATOLOGY

Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C Chueh, Judy Doherty, Francois Vaillant, Gwo-Yaw Ho, Matthew J Wakefield, Clare E Weeden, Alvin Kamili, Jayne Murray, Sela T Po'uha, Janet Weinstock, Serena R Kane, Maree C Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J Kershaw, et al.

Journal article  |  2021  |  CELL DEATH & DISEASE

Targeting cell division by chemotherapy is a highly effective strategy to treat a wide range of cancers. However, there are limita..